FLT3 and acute myeloid leukemia: The third phase of the FLT3-mutated AML treatment regimen is maintenance therapy, which the FDA defines as a prolonged but time-limited course of treatment that is usually less toxic, given after the achievement of CR has been reached to reduce the risk of relapse.